| Code | CSB-RA010327MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TAK-701, specifically targeting hepatocyte growth factor (HGF). HGF is a pleiotropic cytokine that binds to the MET receptor tyrosine kinase, initiating signaling cascades critical for cell proliferation, survival, motility, and morphogenesis. This growth factor plays essential roles in tissue regeneration and embryonic development, but aberrant HGF/MET pathway activation is implicated in tumor growth, metastasis, and angiogenesis across multiple cancer types. Elevated HGF levels have been associated with poor prognosis in various malignancies, including hepatocellular carcinoma, gastric cancer, and non-small cell lung cancer.
TAK-701 is an investigational therapeutic antibody designed to neutralize HGF, thereby blocking its interaction with the MET receptor and inhibiting downstream oncogenic signaling. This biosimilar provides researchers with a valuable tool for investigating HGF/MET pathway biology, exploring mechanisms of tumor progression and metastasis, and evaluating potential therapeutic interventions in oncology and regenerative medicine research. The antibody enables detailed studies of HGF-mediated cellular processes in various experimental models.
There are currently no reviews for this product.